Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Edoxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | F5 | P12259 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edoxaban SCHEMBL716662 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL715418 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL16543780 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL12320151 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL1504007 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL713017 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL715737 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL2125499 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL1312016 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL715818 | 1.00 | F10 (1.00) | F10F2F5PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2972 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739305-A1 | BUDIODARONE FOR CARDIOVERSION | Xyra, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| CN-118108635-B | Preparation method of high-purity edoxaban intermediate | 广西奕安泰药业有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | claimed |
| US-20260071253-A1 | METHOD FOR DETECTING THE PRESENCE, IDENTIFICATION AND QUANTIFICATION IN A BLOOD SAMPLE OF ANTICOAGULANTS WHICH ARE BLOOD COAGULATION ENZYMES INHIBITORS, AND MEANS FOR THE IMPLEMENTATION THEREOF | STAGO DIAGNOSTICA (FR) | 2026-03-12 | — | — | US | claimed |
| EP-4694945-A1 | MEDICAL DEVICES INCLUDING THERAPEUTIC COATINGS FOR LOCAL DELIVERY OF A DIRECT ANTICOAGULANT | Boston Scientific Scimed Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-12553905-B2 | Devices and methods for plasma separation and metering | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2026-02-17 | — | — | US | claimed |
| EP-4438592-B1 | EDOXABAN INTERMEDIATE AND PREPARATION METHOD THEREFOR | SHANGHAI BIOS TECH CO LTD (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-2383272-A1 | ACTIVE BLOOD COAGULATION FACTOR INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2011-11-02 | — | — | EP | claimed |
| US-20110257401-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-20 | — | — | US | claimed |
| EP-2374456-A1 | ACTIVATED BLOOD COAGULATION FACTOR X (FXA) INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | claimed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | claimed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| US-20100081685-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | claimed |
| EP-2140867-A1 | PHARMACEUTICAL COMPOSITION | Daiichi Sankyo Company, Limited (JP) | 2010-01-06 | — | — | EP | claimed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | claimed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | claimed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | claimed |